Prosecutors in New York say Novartis Pharmaceuticals Corp. improperly gave referrals and rebates to a pharmacy in exchange for recommending refills of a drug for blood transfusion patients.
Prosecutors amended an already-filed civil complaint alleging a separate kickback scheme against the East Hanover, N.J.-based company in Manhattan federal court Wednesday.
New York Attorney General Eric Schneiderman says the Elmsford, N.Y.-based pharmacy, BioScrip, illegally submitted claims to Medicare and Medicaid over the drug Exjade, for which it received kickbacks. He says BioScrip paid $15 million to resolve the charges.
Exjade is prescribed to people with chronic iron overload from blood transfusions. It has potentially fatal side effects.
In a statement, Novartis disputed the allegations and said patient safety was its highest priority.
A BioScrip spokesman didn't return a message seeking comment.